Literature DB >> 14708070

Inflammation and nutrition in renal insufficiency.

Kamyar Kalantar-Zadeh1, Peter Stenvinkel, Luana Pillon, Joel D Kopple.   

Abstract

Protein-energy malnutrition (PEM) and inflammation are common in patients with chronic kidney disease (CKD) and worsen as the CKD progresses toward the end-stage renal disease (ESRD). These conditions are major predictors of poor clinical outcome in kidney failure, as reflected by a strong association between hypoalbuminemia and cardiovascular disease (CVD). It has been suggested that inflammation is the cause of both PEM and CVD and, hence, the main link among these conditions, but these hypotheses are not well established. Increased release or activation of inflammatory cytokines, such as interleukin-6 or tumor necrosis factor alpha, may suppress appetite, cause muscle proteolysis and hypoalbuminemia, and may be involved in atherogenesis. Increasing serum levels of proinflammatory cytokines caused by reduced renal function, volume overload, oxidative or carbonyl stress, decreased levels of antioxidants, increased susceptibility to infection in uremia, and the presence of comorbid conditions may lead to inflammation in CKD patients. In hemodialysis patients, the exposure to dialysis tubing and dialysis membranes, poor quality of dialysis water, back-filtration or back-diffusion of contaminants, and foreign bodies in dialysis access maybe additional causes of inflammation. Similarly, episodes of overt or latent peritonitis, peritoneal dialysis (PD) catheter and its related infections, and constant exposure to PD solution may contribute to inflammation in these patients. The degree to which PEM in dialysis patients is caused by inflammation is not clear. Because both PEM and inflammation are strongly associated with each other and can change many nutritional measures and outcome concurrently in the same direction, the terms malnutrition-inflammation complex syndrome (MICS) and/or malnutrition-inflammation-atherosclerosis (MIA) have been suggested to denote the important contribution of both of these conditions to poor clinical outcome. Maintenance dialysis patients who are underweight or who have low serum levels of cholesterol, creatinine, or homocysteine may be suffering from the MICS/MIA and its subsequent poor outcome. Consequently, obesity and hypercholesterolemia may appear protective, which is known as reverse epidemiology. Although MICS/MIA may have a significant contribution in reversing the traditional CVD risk factors in dialysis patients, it is not clear whether PEM or inflammation and their complications can be effectively managed in CKD and ESRD or whether their management improves clinical outcome.

Entities:  

Mesh:

Year:  2003        PMID: 14708070     DOI: 10.1053/j.arrt.2003.08.008

Source DB:  PubMed          Journal:  Adv Ren Replace Ther        ISSN: 1073-4449


  22 in total

1.  No difference in meeting hemoglobin and albumin targets for dialyzed children with urologic disorders.

Authors:  Rachel M Lestz; Meredith Atkinson; Barbara Fivush; Susan L Furth
Journal:  Pediatr Nephrol       Date:  2011-03-20       Impact factor: 3.714

2.  Inflammatory status in chronic renal failure: The role of homocysteinemia and pro-inflammatory cytokines.

Authors:  Hadja Fatima Tbahriti; Djamel Meknassi; Rachid Moussaoui; Amar Messaoudi; Lakhdar Zemour; Abbou Kaddous; Malika Bouchenak; Khedidja Mekki
Journal:  World J Nephrol       Date:  2013-05-06

3.  Quantitative measurement of brain iron deposition in patients with haemodialysis using susceptibility mapping.

Authors:  Chao Chai; Shuo Yan; Zhiqiang Chu; Tong Wang; Lijun Wang; Mengjie Zhang; Chao Zuo; E Mark Haacke; Shuang Xia; Wen Shen
Journal:  Metab Brain Dis       Date:  2014-09-03       Impact factor: 3.584

4.  Oral ghrelin receptor agonist MK-0677 increases serum insulin-like growth factor 1 in hemodialysis patients: a randomized blinded study.

Authors:  Garland A Campbell; James T Patrie; Bruce D Gaylinn; Michael O Thorner; Warren K Bolton
Journal:  Nephrol Dial Transplant       Date:  2018-03-01       Impact factor: 5.992

5.  Anti-Inflammatory and Anti-Oxidative Nutrition in Hypoalbuminemic Dialysis Patients (AIONID) study: results of the pilot-feasibility, double-blind, randomized, placebo-controlled trial.

Authors:  Manoch Rattanasompattikul; Miklos Z Molnar; Martin L Lee; Ramanath Dukkipati; Rachelle Bross; Jennie Jing; Youngmee Kim; Anne C Voss; Debbie Benner; Usama Feroze; Iain C Macdougall; John A Tayek; Keith C Norris; Joel D Kopple; Mark Unruh; Csaba P Kovesdy; Kamyar Kalantar-Zadeh
Journal:  J Cachexia Sarcopenia Muscle       Date:  2013-09-20       Impact factor: 12.910

Review 6.  Inflammation and nutrition in children with chronic kidney disease.

Authors:  Juan Tu; Wai W Cheung; Robert H Mak
Journal:  World J Nephrol       Date:  2016-05-06

Review 7.  Inflammation and cachexia in chronic kidney disease.

Authors:  Wai W Cheung; Kyung Hoon Paik; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-01-29       Impact factor: 3.714

8.  CKD Stimulates Muscle Protein Loss Via Rho-associated Protein Kinase 1 Activation.

Authors:  Hui Peng; Jin Cao; Rizhen Yu; Farhad Danesh; Yanlin Wang; William E Mitch; Jing Xu; Zhaoyong Hu
Journal:  J Am Soc Nephrol       Date:  2015-06-08       Impact factor: 10.121

9.  Anthropometrics Identify Wasting in Patients Undergoing Surgery for Encapsulating Peritoneal Sclerosis.

Authors:  Rosalind Campbell; Titus Augustine; Helen Hurst; Ravi Pararajasingam; David van Dellen; Sheilagh Armstrong; Carol Bartley; Linda Birtles; Angela Summers
Journal:  Perit Dial Int       Date:  2014-03-01       Impact factor: 1.756

10.  Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.

Authors:  Krista L Lentine; Julie Parsonnet; Isabella Taylor; Elizabeth M Wrone; Richard A Lafayette
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.